Sagimet Biosciences Inc. (SGMT)
(Real Time Quote from BATS)
$9.16 USD
+0.71 (8.40%)
Updated Aug 5, 2025 10:26 AM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SGMT 9.16 +0.71(8.40%)
Will SGMT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SGMT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SGMT
What Makes Sagimet Biosciences Inc. (SGMT) a Strong Momentum Stock: Buy Now?
Wall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's What You Should Know
SGMT: What are Zacks experts saying now?
Zacks Private Portfolio Services
SGMT Stock Up 12.6% on FDA Fast Track for Liver Disease Drug
Other News for SGMT
Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference | ...
Sagimet Biosciences (SGMT) Gains on Canaccord Genuity's Positive Outlook
Sagimet gains as Canaccord Genuity starts with Buy on potential against MASH
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday
Sagimet Biosciences (SGMT) Receives 'Buy' Rating from Canaccord Genuity | SGMT Stock News